Jiangsu Sihuan Bioengineering Co (000518) Fair Value & Analysis
Healthcare · CN · Market cap 3.2B CNY
Fair value as of: Jul 21, 2026
From 7 valuation models · updated 20 days ago
Fair value updated Jul 21, 2026, revised from ¥1.46 to ¥0.9200 (−37.0%) since Jun 25, 2026. Share price +16.8% over the past month.
A solid business, but screening 78% overvalued on our models.
What matters now
- A high-quality business (quality 70/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case (¥1.20). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (¥0.6400 to ¥1.20) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range ¥1.79 – ¥4.57 · fair‑value band ¥0.6400 – ¥1.20 · the ¥4.17 price screens above the ¥0.9200 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 21, 2026.
Analysis
Jiangsu Sihuan Bioengineering Co (000518) currently trades at ¥4.17, while our model-based Fair Value estimate is ¥0.9200, implying the stock looks roughly 77.9% overvalued today. The Quality Score stands at 70/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Jiangsu Sihuan Bioengineering Co generated revenue of 382M CNY at a net margin of -8.5%. Revenue grew 85.1% year over year. It earns a return on equity of -9.5%. Net debt stands at 22.6M CNY. Fundamentals as of Jul 21, 2026
Our scenario range runs from ¥0.6400 (bear case) to ¥1.20 (bull case); at ¥4.17, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 8% below its 52-week high and 89% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -78%, 000518 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 7 models by family
Widest divergence: DCF Models (¥1.86) versus Asset-Based (¥0.2200). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 72 · Market factors (momentum, volatility) 82
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Jiangsu Sihuan Bioengineering Co., Ltd., together with its subsidiaries, engages in the production and sales of biopharmaceutical products in China and internationally.
Full company description
Jiangsu Sihuan Bioengineering Co., Ltd., together with its subsidiaries, engages in the production and sales of biopharmaceutical products in China and internationally. The company offers Delusen and New Delusen, a human interleukin-2 for injection are immunomodulators used for the biotherapy of tumors and treatment of patients with weakened immune function; Xinlisheng, a human granulocyte colony-stimulating factor injection used to treat neutropenia caused by bone marrow transplantation, cancer chemotherapy, myelodysplastic syndrome, and aplastic anemia; and Huanerbo, a human erythropoietin injection used to treat symptoms, such as anemia caused by renal insufficiency. It is also involved in the provision of flower planting; forest and natural ecosystem management and protection; forest improvement; forestry product sales; Chinese herbal medicine planting; landscaping project construction; urban municipal greening management; scenic area management; municipal facilities management; earthwork construction; engineering management services; forest park management and design management; external contracting; project cost consulting services; and sale of metal material, agricultural and sideline product, and building and decoration material. Jiangsu Sihuan Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Jiangyin, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Jiangsu Sihuan Bioengineering Co reported revenue of ¥344M in FY2025 versus ¥351M in FY2021, a compound −0.5%/yr. Reported net income was −¥37.1M in FY2025.
000518 screens 78% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 603 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Jiangsu Sihuan Bioengineering Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Jiangsu Sihuan Bioengineering Co (000518) overvalued or undervalued?
What is the fair value of 000518?
What is the quality score of 000518?
What is the revenue of Jiangsu Sihuan Bioengineering Co (000518)?
What is the net profit margin of 000518?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Jiangsu Sihuan Bioengineering Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.